{"entity":{"id":"vnx-102","kind":"drug","name":"VNX-102","aka":[],"tldr":"VNX-102 is an experimental in vivo gene therapy from Vironexis Biotherapeutics, in preclinical development for multiple myeloma.","summary":"VNX-102 is an in vivo gene therapy (TransJoin vectorised T-cell engager) from Vironexis Biotherapeutics. A TransJoin vectorised T-cell engager programme against BCMA and GPRC5D for multiple myeloma. Its furthest stage is preclinical development, for multiple myeloma. No clinical trial naming it is registered on ClinicalTrials.gov. Company milestone: '2026-Q1 IND enabling studies available'. It has not been shown to work in people.","status":"preclinical","asOf":"2026-11-03","links":[{"label":"Vironexis Biotherapeutics: vironexis.com","url":"https://vironexis.com"}],"tags":["pipeline"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["bcma","gprc5d"],"drugs":[],"companies":["vironexis-biotherapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"VNX-102","modality":"In vivo gene therapy (TransJoin vectorised T-cell engager)","mechanism":"A TransJoin vectorised T-cell engager programme against BCMA and GPRC5D for multiple myeloma.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/vnx-102/","neighbours":{"target":[{"id":"bcma","kind":"target","name":"BCMA","route":"/targets/bcma/"},{"id":"gprc5d","kind":"target","name":"GPRC5D","route":"/targets/gprc5d/"}],"company":[{"id":"vironexis-biotherapeutics","kind":"company","name":"Vironexis Biotherapeutics","route":"/companies/vironexis-biotherapeutics/"}]}}